<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3363520</article-id><article-id pub-id-type="publisher-id">cc10709</article-id><article-id pub-id-type="doi">10.1186/cc10709</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Effects of salbutamol on airway characteristics in mechanically ventilated adults without COPD</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Van Rosmalen</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Habes</surname><given-names>QL</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Havinga</surname><given-names>I</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Van Beers</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Van Hees</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Ramnarain</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Van Oers</surname><given-names>JA</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>St Elisabeth Hospital, Tilburg, the Netherlands</aff><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2012</year></pub-date><volume>16</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">32nd International Symposium on Intensive Care and Emergency Medicine</named-content></supplement><fpage>P102</fpage><lpage>P102</lpage><permissions><copyright-statement>Copyright &#x000a9;2012 Van Rosmalen et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Van Rosmalen et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/16/S1/P102"/><conference><conf-date>20-23 March 2012</conf-date><conf-name>32nd International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>In our ICU, salbutamol inhalation to prevent bronchospasm is standard care in mechanically ventilated (MV) patients. In MV patients without COPD the effect of salbutamol remains unclear. Therefore we examined the effect of inhaled salbutamol on resistance and compliance in MV patients without COPD.</p></sec><sec sec-type="methods"><title>Methods</title><p>In this prospective study, we enrolled 11 critically ill MV patients without COPD. These intubated patients were on volume-controlled ventilation (6 ml/kg/PBW). Exclusion criteria were the use of &#x003b2;-blockers, propofol or neuromuscular blockers. They received five puffs of salbutamol (100 &#x003bc;g/puff ) delivered by metered dose inhaler via the adapter on the Y-piece. Ventilator settings and body position were unchanged during the study. Before and after salbutamol administration vital signs were recorded and lung mechanics were measured using the ventilator (Servo-i<sup>&#x000ae; </sup>or Hamilton-G5<sup>&#x000ae;</sup>) at -1, +1, +15, +30, +60, +90 and +240 minutes. Values after administration of salbutamol (T0) were compared to those before administration. Results are presented as mean &#x000b1; SD. Data were evaluated by paired <italic>t </italic>test and <italic>P </italic>&#x0003c; 0.05 was taken as statistically significant.</p></sec><sec sec-type="results"><title>Results</title><p>The study group consisted of seven men and four women, mean age 53 years. Underlying causes for ventilation were diverse. The median time spent on the ventilator before inclusion was 36 hours (6 to 151). After salbutamol administration inspiratory resistance and dynamic compliance decreased, but not significantly. Expiratory resistance, dynamic compliance, elastance, SpO<sub>2 </sub>and EtCO<sub>2 </sub>did not change (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">T-1</th><th align="center">T0</th><th align="center">T+1</th><th align="center">T+15</th><th align="center">T+30</th><th align="center" colspan="2">T+60</th><th align="center">T+90</th><th align="center">T+240</th><th/></tr></thead><tbody><tr><td align="left">R<sub>ins </sub>(cm H<sub>2</sub>O/l/second)</td><td align="center">14 (6)</td><td align="center">Salbutamol administration</td><td align="center">14 (4)</td><td align="center">13 (5)</td><td align="center">13 (5)</td><td align="center" colspan="2">12 (4)</td><td align="center">12 (5)</td><td align="center">12 (4)</td><td align="center">NS</td></tr><tr><td align="left">R<sub>exp </sub>(cm H<sub>2</sub>O/l/second)</td><td align="center">17 (7)</td><td/><td align="center">17 (6)</td><td align="center">16 (6)</td><td align="center">17 (8)</td><td align="center">18</td><td align="center">(10)</td><td align="center">18 (8)</td><td align="center">17 (7)</td><td align="center">NS</td></tr><tr><td align="left">C<sub>dyn </sub>(ml/cm H<sub>2</sub>O)</td><td align="center">44 (12)</td><td/><td align="center">42 (11)</td><td align="center">42 (11)</td><td align="center">37 (10)</td><td align="center" colspan="2">36 (9)</td><td align="center">38 (9)</td><td align="center">38 (8)</td><td align="center">NS</td></tr><tr><td align="left">C<sub>stat </sub>(ml/cm H<sub>2</sub>O)</td><td align="center">49 (13)</td><td/><td align="center">49 (12)</td><td align="center">47 (13)</td><td align="center">43 (11)</td><td align="center" colspan="2">44 (12)</td><td align="center">45 (12)</td><td align="center">43 (12)</td><td align="center">NS</td></tr><tr><td align="left">Elastance (cm H<sub>2</sub>O/l)</td><td align="center">19 (3)</td><td/><td align="center">20 (4)</td><td align="center">21 (4)</td><td align="center">22 (4)</td><td align="center" colspan="2">23 (4)</td><td align="center">21 (4)</td><td align="center">18 (8)</td><td align="center">NS</td></tr><tr><td align="left">Heart rate (beats/minute)</td><td align="center">81 (22)</td><td/><td align="center">84 (24)</td><td align="center">85 (23)</td><td align="center">87 (22)</td><td align="center" colspan="2">85 (22)</td><td align="center">82 (18)</td><td align="center">84 (20)</td><td align="center">NS</td></tr><tr><td align="left">SpO<sub>2 </sub>(%)</td><td align="center">98 (1)</td><td/><td align="center">98 (2)</td><td align="center">98 (2)</td><td align="center">98 (1)</td><td align="center" colspan="2">98 (2)</td><td align="center">98 (2)</td><td align="center">97 (2)</td><td align="center">NS</td></tr><tr><td align="left">EtCO<sub>2 </sub>(kPa)</td><td align="center">4.7 (0.7)</td><td/><td align="center">4.7 (0.7)</td><td align="center">4.7 (0.7)</td><td align="center">4.7 (0.7)</td><td align="center" colspan="2">4.7 (0.7)</td><td align="center">4.7 (0.8)</td><td align="center">4.7 (0.7)</td><td align="center">NS</td></tr></tbody></table></table-wrap></sec><sec sec-type="conclusions"><title>Conclusion</title><p>There was no significant effect of salbutamol inhalation on airway characteristics and vital signs in non-COPD patients on MV. Therefore standard salbutamol inhalation in MV patients without COPD can be aborted.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Malliotakis</surname><given-names>P</given-names></name><etal/><article-title>Influence of respiratory efforts on &#x003b2;<sub>2</sub>-agonist induced bronchodilation in mechanically ventilated COPD patients: a prospective clinical study</article-title><source>Respir Med</source><year>2007</year><volume>101</volume><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2006.05.002</pub-id><pub-id pub-id-type="pmid">16774821</pub-id></mixed-citation></ref></ref-list></back></article>